US2008234365A1PendingUtilityA1
Non-nuclear effects of thyroid hormone
Est. expiryJun 28, 2020(expired)· nominal 20-yr term from priority
G01N 33/78G01N 2500/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Truncated thyroid hormone receptors ΔTRα1 and ΔTRα2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ΔTRα1 and ΔTRα2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
Claims
exact text as granted — not AI-modified1 - 21 . (canceled)
22 . A method of treating a subject who has a neurologic disorder, the method comprising administering to the subject a therapeutically effective amount of a ΔTRα2 ligand.
23 . A method of treating an individual who has a mood disorder, the method comprising administering to the individual a therapeutically effective amount of a ΔTRα2 ligand.
24 - 45 . (canceled)
46 . The method of claim 22 , wherein the disorder is selected from the group consisting of bipolar disorder, major depression, attention deficit disorder, attention deficit hyperactivity disorder, and obsessive-compulsive disorder.
47 . The method of claim 23 , wherein the disorder is depression.
48 . The method of claim 23 , wherein the disorder is postpartum depression.
49 . The method of claim 22 , wherein the ΔTRα2 ligand is a flavone.
50 . The method of claim 23 , wherein the ΔTRα2 ligand is a flavone.
51 . The method of claim 22 , wherein the ΔTRα2 ligand is an aurone.
52 . The method of claim 23 , wherein the ΔTRα2 ligand is an auroneJoin the waitlist — get patent alerts
Track US2008234365A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.